Walter Plöchl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Walter Plöchl has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
- David J. Cook
Department of Anesthesiology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
8 shared publications - Joanna Baron-Stefaniak
Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna, Vienna, Austria
4 shared publications - Judith Schiefer
Universitätsklinik für Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie, Medizinische Universität Wien, Wien, Österreich
4 shared publications Thomas A. Orszulak
4 shared publicationsRichard C. Daly
3 shared publications- Thomas Hamp
Emergency Medical Service Vienna, Vienna, Austria
3 shared publications
Latest Publications
- 31 July 2025
- Published by MyJove Corporation
- No. 221,p. e68520
JoVE Video Dataset
When using volatile anesthetic agents, the standard measure of potency is the minimum alveolar concentration (MAC), defined as the alveolar concentration at which 50% of subjects do not show a motor response to a painful stimulus. In clinical and experimental studies, the current consensus states that only "gross purposeful movements" count as a positive motor response and can, therefore, indicate too mild sedation. However, the appropriate level of anesthesia, in both humans and animals, varies individually based on various influencing factors, such as other medications administered. Two animal studies in rats were conducted to examine the effects of tetrahydrocannabinol and ethanol on sevoflurane, one of the most commonly used volatile anesthetics. To estimate the MAC, Dixon's Up-and-Down Design was employed. For the first animal, a predetermined dose of sevoflurane was chosen. After an equilibration period of 15 min, a standardized pain stimulus was applied to the distal third of the rat's tail using a surgical clamp. The animal's response to the stimulus was documented as positive or negative. If a positive motor reaction occurred, the dose for the next animal was increased. Conversely, if the rat did not exhibit a motor response, the dose for the following animal was decreased. Isotonic regression and the bootstrap method were used to estimate the MAC and 95% confidence intervals. This article outlines a detailed protocol for assessing anesthetic depth in rats using the up-and-down-design. It also provides a novel and detailed description and categorization of movement patterns in sedated rats when a standardized painful stimulus is applied to enhance reproducibility for future studies.
- 31 July 2025
- Published by MyJove Corporation
- No. 221,p. e68520
JoVE Video Dataset
When using volatile anesthetic agents, the standard measure of potency is the minimum alveolar concentration (MAC), defined as the alveolar concentration at which 50% of subjects do not show a motor response to a painful stimulus. In clinical and experimental studies, the current consensus states that only "gross purposeful movements" count as a positive motor response and can, therefore, indicate too mild sedation. However, the appropriate level of anesthesia, in both humans and animals, varies individually based on various influencing factors, such as other medications administered. Two animal studies in rats were conducted to examine the effects of tetrahydrocannabinol and ethanol on sevoflurane, one of the most commonly used volatile anesthetics. To estimate the MAC, Dixon's Up-and-Down Design was employed. For the first animal, a predetermined dose of sevoflurane was chosen. After an equilibration period of 15 min, a standardized pain stimulus was applied to the distal third of the rat's tail using a surgical clamp. The animal's response to the stimulus was documented as positive or negative. If a positive motor reaction occurred, the dose for the next animal was increased. Conversely, if the rat did not exhibit a motor response, the dose for the following animal was decreased. Isotonic regression and the bootstrap method were used to estimate the MAC and 95% confidence intervals. This article outlines a detailed protocol for assessing anesthetic depth in rats using the up-and-down-design. It also provides a novel and detailed description and categorization of movement patterns in sedated rats when a standardized painful stimulus is applied to enhance reproducibility for future studies.
- 25 July 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 221,p. e68520
Application of Dixon's Up-and-Down Design to Estimate the Minimum Alveolar Concentration of Sevoflurane in Rats with Refined Movement Classification
When using volatile anesthetic agents, the standard measure of potency is the minimum alveolar concentration (MAC), defined as the alveolar concentration at which 50% of subjects do not show a motor response to a painful stimulus. In clinical and experimental studies, the current consensus states that only "gross purposeful movements" count as a positive motor response and can, therefore, indicate too mild sedation. However, the appropriate level of anesthesia, in both humans and animals, varies individually based on various influencing factors, such as other medications administered. Two animal studies in rats were conducted to examine the effects of tetrahydrocannabinol and ethanol on sevoflurane, one of the most commonly used volatile anesthetics. To estimate the MAC, Dixon's Up-and-Down Design was employed. For the first animal, a predetermined dose of sevoflurane was chosen. After an equilibration period of 15 min, a standardized pain stimulus was applied to the distal third of the rat's tail using a surgical clamp. The animal's response to the stimulus was documented as positive or negative. If a positive motor reaction occurred, the dose for the next animal was increased. Conversely, if the rat did not exhibit a motor response, the dose for the following animal was decreased. Isotonic regression and the bootstrap method were used to estimate the MAC and 95% confidence intervals. This article outlines a detailed protocol for assessing anesthetic depth in rats using the up-and-down-design. It also provides a novel and detailed description and categorization of movement patterns in sedated rats when a standardized painful stimulus is applied to enhance reproducibility for future studies.
- 25 July 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 221,p. e68520
Application of Dixon's Up-and-Down Design to Estimate the Minimum Alveolar Concentration of Sevoflurane in Rats with Refined Movement Classification
When using volatile anesthetic agents, the standard measure of potency is the minimum alveolar concentration (MAC), defined as the alveolar concentration at which 50% of subjects do not show a motor response to a painful stimulus. In clinical and experimental studies, the current consensus states that only "gross purposeful movements" count as a positive motor response and can, therefore, indicate too mild sedation. However, the appropriate level of anesthesia, in both humans and animals, varies individually based on various influencing factors, such as other medications administered. Two animal studies in rats were conducted to examine the effects of tetrahydrocannabinol and ethanol on sevoflurane, one of the most commonly used volatile anesthetics. To estimate the MAC, Dixon's Up-and-Down Design was employed. For the first animal, a predetermined dose of sevoflurane was chosen. After an equilibration period of 15 min, a standardized pain stimulus was applied to the distal third of the rat's tail using a surgical clamp. The animal's response to the stimulus was documented as positive or negative. If a positive motor reaction occurred, the dose for the next animal was increased. Conversely, if the rat did not exhibit a motor response, the dose for the following animal was decreased. Isotonic regression and the bootstrap method were used to estimate the MAC and 95% confidence intervals. This article outlines a detailed protocol for assessing anesthetic depth in rats using the up-and-down-design. It also provides a novel and detailed description and categorization of movement patterns in sedated rats when a standardized painful stimulus is applied to enhance reproducibility for future studies.
- Open Access
- 24 June 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (4) , 928-934
Continuous Intravenous Nimodipine Infusion With Ethanol as Carrier in Aneurysmal Subarachnoid Hemorrhage Does Not Result in Measurable Cerebral Ethanol Levels
An unimpaired neurological evaluation is essential for detecting delayed cerebral ischemia (DCI) in aneurysmal subarachnoid hemorrhage (aSAH) patients. Nimodipine is currently the only drug approved for DCI prevention. Intravenous nimodipine infusion contains 23.7 vol% ethanol as an excipient, resulting in up to 45 g of ethanol being infused daily, which may interfere with neurological assessment. Therefore, we aimed to measure ethanol concentrations in plasma, cerebrospinal fluid (CSF), and brain parenchyma during the infusion of 0.5–2 mg of nimodipine per hour in aSAH patients to quantify the ethanol neuronal exposure. Ethanol concentrations were determined by headspace gas chromatography‐flame ionization detection in plasma and CSF and we set out brain parenchyma measurement using cerebral microdialysis, in 10 aSAH patients. In each compartment four samples were taken over a 6‐hour interval during steady‐state intravenous nimodipine infusion at four different doses (0.5, 1, 1.5 and 2 mg/hour). A total of 307 samples from plasma and CSF was measured. Ethanol levels were mostly below the quantification limit of 0.002 g/100 mL. In 36 samples ethanol concentration was ≥ 0.002 g/100 mL, ranging from 0.002 to 0.009 g/100 mL. These low values were not reproducible in a second measurement, suggesting these values likely reflected analytical variability rather than true ethanol concentrations. Nimodipine analysis in brain parenchyma was omitted due to insufficient microdialysate volume and low concentrations in blood and CSF. Continuous nimodipine infusion of up to 2 mg/hour is unlikely to impair neurological assessment in aSAH patients, as no significant CSF ethanol concentration (< 0.002 g/100 mL) was detected.
- 24 June 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (4) , 928-934
Open AccessContinuous Intravenous Nimodipine Infusion With Ethanol as Carrier in Aneurysmal Subarachnoid Hemorrhage Does Not Result in Measurable Cerebral Ethanol Levels
An unimpaired neurological evaluation is essential for detecting delayed cerebral ischemia (DCI) in aneurysmal subarachnoid hemorrhage (aSAH) patients. Nimodipine is currently the only drug approved for DCI prevention. Intravenous nimodipine infusion contains 23.7 vol% ethanol as an excipient, resulting in up to 45 g of ethanol being infused daily, which may interfere with neurological assessment. Therefore, we aimed to measure ethanol concentrations in plasma, cerebrospinal fluid (CSF), and brain parenchyma during the infusion of 0.5–2 mg of nimodipine per hour in aSAH patients to quantify the ethanol neuronal exposure. Ethanol concentrations were determined by headspace gas chromatography‐flame ionization detection in plasma and CSF and we set out brain parenchyma measurement using cerebral microdialysis, in 10 aSAH patients. In each compartment four samples were taken over a 6‐hour interval during steady‐state intravenous nimodipine infusion at four different doses (0.5, 1, 1.5 and 2 mg/hour). A total of 307 samples from plasma and CSF was measured. Ethanol levels were mostly below the quantification limit of 0.002 g/100 mL. In 36 samples ethanol concentration was ≥ 0.002 g/100 mL, ranging from 0.002 to 0.009 g/100 mL. These low values were not reproducible in a second measurement, suggesting these values likely reflected analytical variability rather than true ethanol concentrations. Nimodipine analysis in brain parenchyma was omitted due to insufficient microdialysate volume and low concentrations in blood and CSF. Continuous nimodipine infusion of up to 2 mg/hour is unlikely to impair neurological assessment in aSAH patients, as no significant CSF ethanol concentration (< 0.002 g/100 mL) was detected.
- Open Access
- 19 November 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (2) , 589-597
Cerebral Ischemia Protection After Aneurysmal Subarachnoid Hemorrhage: CSF Nimodipine Levels After Intravenous Versus Oral Nimodipine Administration
There is accumulating evidence that cerebrospinal fluid (CSF) concentrations of nimodipine correlate with long‐term outcome of patients after subarachnoidal hemorrhage (aSAH) by impeding cerebral ischemia. However, pharmacological data on simultaneous serum vs. CSF and intraparenchymal nimodipine values are rarely reported in larger patient groups. Nimodipine concentrations were determined in plasma, CSF, and cerebral interstitial fluid (ISF), at steady state after oral (6 × 60 mg/day) and intravenous (0.5, 1, 1.5 and 2 mg/h) administrations in 10 patients after aSAH. Area under the concentration time curve (AUC0–24) for intravenous nimodipine was highest at an infusion rate of 2 mg/h in plasma (1335.87 ± 591.09 mg*h/L), followed by CSF (39.53 ± 23.07 mg*h/L), resulting in an overall CSF penetration ratio of 3.8% (±1.5) (AUCCSF/AUCplasma). In contrast, nimodipine levels were significantly lower in both plasma (AUC0–24 298.32 ± 206.52 mg*h/L) and CSF (AUC0–24 34.8 ± 16.56 mg*h/L) after oral administration. In cerebral ISF, low amounts of nimodipine were detectable in only 4 patients at an infusion rate of 1.5 and 2 mg/h as well as following oral administration. We found significantly higher CSF nimodipine levels in patients during intravenous compared to oral administration. In contrast, only low amounts of nimodipine were detected in the ISF after both oral and intravenous administration. Our findings strongly suggest that the main clinical nimodipine effect of impeding life threatening cerebral ischemia is mediated through significant higher CSF levels after intravenous administration, more likely effective than oral administration.
- 19 November 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (2) , 589-597
Open AccessCerebral Ischemia Protection After Aneurysmal Subarachnoid Hemorrhage: CSF Nimodipine Levels After Intravenous Versus Oral Nimodipine Administration
There is accumulating evidence that cerebrospinal fluid (CSF) concentrations of nimodipine correlate with long‐term outcome of patients after subarachnoidal hemorrhage (aSAH) by impeding cerebral ischemia. However, pharmacological data on simultaneous serum vs. CSF and intraparenchymal nimodipine values are rarely reported in larger patient groups. Nimodipine concentrations were determined in plasma, CSF, and cerebral interstitial fluid (ISF), at steady state after oral (6 × 60 mg/day) and intravenous (0.5, 1, 1.5 and 2 mg/h) administrations in 10 patients after aSAH. Area under the concentration time curve (AUC0–24) for intravenous nimodipine was highest at an infusion rate of 2 mg/h in plasma (1335.87 ± 591.09 mg*h/L), followed by CSF (39.53 ± 23.07 mg*h/L), resulting in an overall CSF penetration ratio of 3.8% (±1.5) (AUCCSF/AUCplasma). In contrast, nimodipine levels were significantly lower in both plasma (AUC0–24 298.32 ± 206.52 mg*h/L) and CSF (AUC0–24 34.8 ± 16.56 mg*h/L) after oral administration. In cerebral ISF, low amounts of nimodipine were detectable in only 4 patients at an infusion rate of 1.5 and 2 mg/h as well as following oral administration. We found significantly higher CSF nimodipine levels in patients during intravenous compared to oral administration. In contrast, only low amounts of nimodipine were detected in the ISF after both oral and intravenous administration. Our findings strongly suggest that the main clinical nimodipine effect of impeding life threatening cerebral ischemia is mediated through significant higher CSF levels after intravenous administration, more likely effective than oral administration.
- Open Access
- 17 July 2019
- Published by Springer Nature in BMC Nephrology
- Vol. 20 (1) , 1-7
Urinary [TIMP-2] × [IGFBP-7] for predicting acute kidney injury in patients undergoing orthotopic liver transplantation
The product of the concentrations of urinary tissue inhibitor of metalloproteinases-2 and insulin-like growth factor binding protein-7 (urinary [TIMP-2] × [IGFBP-7]) has been suggested as biomarker for early detection of acute kidney injury (AKI) in various clinical settings. However, the performance of urinary [TIMP-2] × [IGFBP-7] to predict AKI has never been assessed in patients undergoing orthotopic liver transplantation (OLT). Thus, the aim of this study was to assess the early predictive value of urinary [TIMP-2] × [IGFBP-7] for the development of AKI after OLT. In this observational study, urinary [TIMP-2] × [IGFBP-7] was measured in samples from adult OLT patients. AKI was diagnosed and classified according to KDIGO criteria. Areas under the receiver operating curves (AUC) were calculated to assess predictive values of urinary [TIMP-2] × [IGFBP-7] for the development of AKI. Forty patients (mean age 55 ± 8 years) were included. Twenty-eight patients (70%) developed AKI stage 1, 2, or 3 within 48 h after OLT. Urinary [TIMP-2] × [IGFBP-7] was not predictive for AKI at the end of OLT (AUC: 0.54, CI [0.32–0.75], P = 0.72), at day 1 (AUC: 0.60, CI [0.41–0.79], P = 0.31), or day 2 after OLT (AUC: 0.63, CI [0.46–0.8], P = 0.18). Based on our results, routine clinical use of urinary [TIMP-2] × [IGFBP-7] cannot be recommended for risk assessment of AKI in patients undergoing OLT.
- 17 July 2019
- Published by Springer Nature in BMC Nephrology
- Vol. 20 (1) , 1-7
Open AccessUrinary [TIMP-2] × [IGFBP-7] for predicting acute kidney injury in patients undergoing orthotopic liver transplantation
The product of the concentrations of urinary tissue inhibitor of metalloproteinases-2 and insulin-like growth factor binding protein-7 (urinary [TIMP-2] × [IGFBP-7]) has been suggested as biomarker for early detection of acute kidney injury (AKI) in various clinical settings. However, the performance of urinary [TIMP-2] × [IGFBP-7] to predict AKI has never been assessed in patients undergoing orthotopic liver transplantation (OLT). Thus, the aim of this study was to assess the early predictive value of urinary [TIMP-2] × [IGFBP-7] for the development of AKI after OLT. In this observational study, urinary [TIMP-2] × [IGFBP-7] was measured in samples from adult OLT patients. AKI was diagnosed and classified according to KDIGO criteria. Areas under the receiver operating curves (AUC) were calculated to assess predictive values of urinary [TIMP-2] × [IGFBP-7] for the development of AKI. Forty patients (mean age 55 ± 8 years) were included. Twenty-eight patients (70%) developed AKI stage 1, 2, or 3 within 48 h after OLT. Urinary [TIMP-2] × [IGFBP-7] was not predictive for AKI at the end of OLT (AUC: 0.54, CI [0.32–0.75], P = 0.72), at day 1 (AUC: 0.60, CI [0.41–0.79], P = 0.31), or day 2 after OLT (AUC: 0.63, CI [0.46–0.8], P = 0.18). Based on our results, routine clinical use of urinary [TIMP-2] × [IGFBP-7] cannot be recommended for risk assessment of AKI in patients undergoing OLT.
- 1 December 2018
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 121 (6) , 1242-1248
Effect of intravenous S-ketamine on the MAC of sevoflurane: a randomised, placebo-controlled, double-blinded clinical trial
- 1 December 2018
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 121 (6) , 1242-1248
Effect of intravenous S-ketamine on the MAC of sevoflurane: a randomised, placebo-controlled, double-blinded clinical trial
- 1 September 2017
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 125 (3) , 783-789
Patients Undergoing Orthotopic Liver Transplantation Require Lower Concentrations of the Volatile Anesthetic Sevoflurane
Sevoflurane is a volatile anesthetic commonly used to maintain anesthesia in patients with end-stage liver disease (ESLD) undergoing orthotopic liver transplantation (OLT). Growing evidence suggests that patients with ESLD have decreased anesthetic requirements compared to patients with preserved liver function. The potency of volatile anesthetics is expressed as the minimum alveolar concentration (MAC). In this prospective, blinded study, we compared the MAC of sevoflurane among patients with ESLD undergoing OLT and patients with normal liver function undergoing major abdominal surgery. After propofol-induced anesthesia, the MAC of sevoflurane was assessed by evaluating motor response to initial skin incision in patients undergoing OLT and in patients with normal liver function undergoing major abdominal surgery. The MAC was determined using Dixon “up-and-down” method and compared between groups. In addition, the bispectral index was documented immediately before and after skin incision. Twenty patients undergoing OLT and 20 control patients were included in the study. The MAC of sevoflurane in patients undergoing OLT was 1.3% (95% confidence interval [CI], 1.1–1.4). In comparison, the MAC of sevoflurane in patients with normal liver function was 1.7% (95% CI, 1.6–1.9), equal to a relative reduction of the MAC in patients with ESLD of 26% (95% CI, 14–39). The bispectral index was higher in patients with ESLD than in control patients at 3 minutes before (47 [95% CI, 40–53] vs 35 [95% CI, 31–40], P = .011), 1 minute before (48 [95% CI, 42–54] vs 37 [95% CI, 33–43], P = .03), and 1 minute after skin incision (57 [95% CI, 50–64] vs 41 [95% CI, 36–47], P < .001). Our results suggest that the MAC of sevoflurane is lower in patients with ESLD than in patients with normal liver function after propofol-induced anesthesia. However, as we did not measure propofol concentrations at the time of skin incision, the difference in MAC should be interpreted with caution given that residual propofol may have been present at the time of skin incision.
- 1 September 2017
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 125 (3) , 783-789
Patients Undergoing Orthotopic Liver Transplantation Require Lower Concentrations of the Volatile Anesthetic Sevoflurane
Sevoflurane is a volatile anesthetic commonly used to maintain anesthesia in patients with end-stage liver disease (ESLD) undergoing orthotopic liver transplantation (OLT). Growing evidence suggests that patients with ESLD have decreased anesthetic requirements compared to patients with preserved liver function. The potency of volatile anesthetics is expressed as the minimum alveolar concentration (MAC). In this prospective, blinded study, we compared the MAC of sevoflurane among patients with ESLD undergoing OLT and patients with normal liver function undergoing major abdominal surgery. After propofol-induced anesthesia, the MAC of sevoflurane was assessed by evaluating motor response to initial skin incision in patients undergoing OLT and in patients with normal liver function undergoing major abdominal surgery. The MAC was determined using Dixon “up-and-down” method and compared between groups. In addition, the bispectral index was documented immediately before and after skin incision. Twenty patients undergoing OLT and 20 control patients were included in the study. The MAC of sevoflurane in patients undergoing OLT was 1.3% (95% confidence interval [CI], 1.1–1.4). In comparison, the MAC of sevoflurane in patients with normal liver function was 1.7% (95% CI, 1.6–1.9), equal to a relative reduction of the MAC in patients with ESLD of 26% (95% CI, 14–39). The bispectral index was higher in patients with ESLD than in control patients at 3 minutes before (47 [95% CI, 40–53] vs 35 [95% CI, 31–40], P = .011), 1 minute before (48 [95% CI, 42–54] vs 37 [95% CI, 33–43], P = .03), and 1 minute after skin incision (57 [95% CI, 50–64] vs 41 [95% CI, 36–47], P < .001). Our results suggest that the MAC of sevoflurane is lower in patients with ESLD than in patients with normal liver function after propofol-induced anesthesia. However, as we did not measure propofol concentrations at the time of skin incision, the difference in MAC should be interpreted with caution given that residual propofol may have been present at the time of skin incision.
- 21 April 2017
- Published by Wiley in Clinical Transplantation
- Vol. 31 (6)
Graft‐derived macrophage migration inhibitory factor correlates with hepatocellular injury in patients undergoing liver transplantation
Experimental studies suggest that macrophage migration inhibitory factor (MIF) mediates ischemia/reperfusion injury during liver transplantation. This study assessed whether human liver grafts release MIF during preservation, and whether the release of MIF is proportional to the extent of hepatocellular injury. Additionally, the association between MIF and early allograft dysfunction (EAD) after liver transplantation was evaluated. Concentrations of MIF, aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), and creatine kinase (CK) were measured in effluents of 38 liver grafts, and in serum of recipients. Concentrations of MIF in the effluent were greater than those in the recipients’ serum before and after reperfusion (58 [interquartile range, IQR:23‐79] μg/mL vs 0.06 [IQR:0.03‐0.07] μg/mL and 1.3 [IQR:0.7‐1.8] μg/mL, respectively; both P<.001). Effluent MIF concentrations correlated with effluent concentrations of the cell injury markers ALT (R=.51, P<.01), AST (R=.51, P<.01), CK (R=.45, P=.01), and LDH (R=.56, P<.01). Patients who developed EAD had greater MIF concentrations in effluent and serum 10 minutes after reperfusion than patients without EAD (Effluent: 80 [IQR:63‐118] μg/mL vs 36 [IQR:20‐70] μg/mL, P=.02; Serum: 1.7 [IQR:1.2‐2.5] μg/mL vs 1.1 [IQR:0.6‐1.7] μg/mL, P<.001).Conclusion: Human liver grafts release MIF in proportion to hepatocellular injury. Greater MIF concentrations in effluent and recipient's serum are associated with EAD after liver transplantation.
- 21 April 2017
- Published by Wiley in Clinical Transplantation
- Vol. 31 (6)
Graft‐derived macrophage migration inhibitory factor correlates with hepatocellular injury in patients undergoing liver transplantation
Experimental studies suggest that macrophage migration inhibitory factor (MIF) mediates ischemia/reperfusion injury during liver transplantation. This study assessed whether human liver grafts release MIF during preservation, and whether the release of MIF is proportional to the extent of hepatocellular injury. Additionally, the association between MIF and early allograft dysfunction (EAD) after liver transplantation was evaluated. Concentrations of MIF, aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), and creatine kinase (CK) were measured in effluents of 38 liver grafts, and in serum of recipients. Concentrations of MIF in the effluent were greater than those in the recipients’ serum before and after reperfusion (58 [interquartile range, IQR:23‐79] μg/mL vs 0.06 [IQR:0.03‐0.07] μg/mL and 1.3 [IQR:0.7‐1.8] μg/mL, respectively; both P<.001). Effluent MIF concentrations correlated with effluent concentrations of the cell injury markers ALT (R=.51, P<.01), AST (R=.51, P<.01), CK (R=.45, P=.01), and LDH (R=.56, P<.01). Patients who developed EAD had greater MIF concentrations in effluent and serum 10 minutes after reperfusion than patients without EAD (Effluent: 80 [IQR:63‐118] μg/mL vs 36 [IQR:20‐70] μg/mL, P=.02; Serum: 1.7 [IQR:1.2‐2.5] μg/mL vs 1.1 [IQR:0.6‐1.7] μg/mL, P<.001).Conclusion: Human liver grafts release MIF in proportion to hepatocellular injury. Greater MIF concentrations in effluent and recipient's serum are associated with EAD after liver transplantation.
- 1 June 2016
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 116 (6) , 797-803
Feasibility of a ‘reversed’ isolated forearm technique by regional antagonization of rocuronium-induced neuromuscular block: a pilot study
The trial was registered at EudraCT (ref. no. 2013-002164-53) before patient enrolment began.
- 1 June 2016
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 116 (6) , 797-803
Feasibility of a ‘reversed’ isolated forearm technique by regional antagonization of rocuronium-induced neuromuscular block: a pilot study
The trial was registered at EudraCT (ref. no. 2013-002164-53) before patient enrolment began.
- 18 April 2016
- Published by Morressier GmbH
The effect of intravenous s-ketamine on the MAC of sevoflurane, preliminary results
Welcome to the largest platform for early-stage research
- 18 April 2016
- Published by Morressier GmbH
The effect of intravenous s-ketamine on the MAC of sevoflurane, preliminary results
Welcome to the largest platform for early-stage research